Free Trial

PetVivo Q3 2024 Earnings Report

PetVivo logo
$0.55 +0.01 (+1.80%)
As of 03/3/2025 01:34 PM Eastern

PetVivo EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PetVivo Revenue Results

Actual Revenue
$0.60 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PetVivo Announcement Details

Quarter
Q3 2024
Time
N/A

Conference Call Resources

PetVivo Earnings Headlines

PetVivo, Digital Landia announce partnership for Agentic AI solutions
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
See More PetVivo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetVivo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetVivo and other key companies, straight to your email.

About PetVivo

PetVivo (NASDAQ:PETV), a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

View PetVivo Profile

More Earnings Resources from MarketBeat